zoledronic acid has been researched along with Cardiac Failure in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deftereos, S; Drakopoulou, M; Giannopoulos, G; Kaitozis, O; Latsios, G; Papanikolaou, A; Stathogiannis, K; Synetos, A; Tousoulis, D; Toutouzas, K; Trantalis, G | 1 |
| Anagnostis, P; Anastasilakis, AD; Arsos, G; Kita, M; Moralidis, E; Papatheodorou, A; Polyzos, SA; Terpos, E | 1 |
| Hussar, DA | 1 |
| Schwetz, BA | 1 |
1 review(s) available for zoledronic acid and Cardiac Failure
| Article | Year |
|---|---|
Therapeutic Applications of Calcium Metabolism Modulation in Heart Disease.
Topics: Animals; Arrhythmias, Cardiac; Calcineurin; Calcium; Calcium-Binding Proteins; Cyclic AMP-Dependent Protein Kinases; Diphosphonates; Heart Diseases; Heart Failure; Humans; Imidazoles; MicroRNAs; Myocardial Ischemia; Ryanodine Receptor Calcium Release Channel; S100 Proteins; Sarcoplasmic Reticulum Calcium-Transporting ATPases; SUMO-1 Protein; Vitamin D; Zoledronic Acid | 2016 |
3 other study(ies) available for zoledronic acid and Cardiac Failure
| Article | Year |
|---|---|
Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Disease Progression; Fatal Outcome; Female; Health Status; Heart Failure; Humans; Imidazoles; Osteitis Deformans; Treatment Outcome; Zoledronic Acid | 2012 |
New drugs 2002, part III.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Antihypertensive Agents; Antirheumatic Agents; Bone Resorption; Bosentan; Cephalosporins; Darbepoetin alfa; Diphosphonates; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Erythropoietin; Heart Failure; Humans; Hypoglycemic Agents; Imidazoles; Indoles; Insulin; Insulin Aspart; Interleukin 1 Receptor Antagonist Protein; Natriuretic Agents; Natriuretic Peptide, Brain; Organophosphonates; Organophosphorus Compounds; Protein C; Recombinant Proteins; Serotonin Receptor Agonists; Sialoglycoproteins; Sulfonamides; Tenofovir; Tryptamines; Zoledronic Acid | 2002 |
From the Food and Drug Administration.
Topics: Atrial Natriuretic Factor; Cardiotonic Agents; Diphosphonates; Equipment Reuse; Heart Failure; Humans; Hypercalcemia; Imidazoles; Natriuretic Peptide, Brain; Neoplasms; United States; United States Food and Drug Administration; Zoledronic Acid | 2001 |